To date, several studies have provided validation of targeting CAIX in multiple tumor models [14,15,16,17] and an array of potential therapeutic strategies to target CAIX have been developed, including the use of small molecule inhibitors of CAIX/CAXII activity [6,7]. The gene discussed is CA12; the disease is neoplasm.